Abstract
The treatment landscape for metastatic castrate-sensitive prostate cancer has changed dramatically in the past decade because of the approval of chemotherapy and novel androgen therapies in combination with androgen deprivation therapy. The addition of these agents has resulted in overall benefits and progression-free survival for patients. The National Institute for Health and Care Excellence recently approved enzalutamide in the treatment of metastatic castrate-sensitive prostate cancer. Oncology nurse prescribers are central to the care of prostate cancer, providing holistic assessment and management of the disease and treatment side effects. A comprehensive understanding of the mechanism of action and specific side effects of androgen receptor inhibitors will enable an oncology nurse to provide timely interventions with a high standard of care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
